MicroRNA‑145 promotes the apoptosis of leukemic�stem�cells and enhances drug‑resistant K562/ADM cell�sensitivity to adriamycin via the regulation of ABCE1-Reference-Cited by-同舟云学术

MicroRNA‑145 promotes the apoptosis of leukemic�stem�cells and enhances drug‑resistant K562/ADM cell�sensitivity to adriamycin via the regulation of ABCE1

Published:2020-07-15 Issue: Volume: Page:
ISSN:1107-3756
Container-title:International Journal of Molecular Medicine
language:
Short-container-title:Int J Mol Med

Author:

Wuxiao Zhijun¹,Wang Hua²,Su Qunhao¹,Zhou Haiyan¹,Hu Min¹,Tao Shi¹,Xu Lu¹,Chen Yu¹,Hao Xinbao¹

Affiliation:

1. Department of Hematology, Lymphoma and Myeloma Center, HMC Cancer Institute, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570102, P.R. China

2. Department of Hematological Oncology, Sun Yat‑sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China

Publisher

Spandidos Publications

Subject

Genetics,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of Human Bone Marrow Mesenchymal Stem Cells Secretome from Acute Myeloid Leukemia Patients on the Proliferation and Death of K562 and K562-Lucena Leukemia Cell Lineages;International Journal of Molecular Sciences;2024-04-26

2. Restoration of miR-299-3p promotes macrophage phagocytosis and suppresses malignant phenotypes in breast cancer carcinogenesis via dual-targeting CD47 and ABCE1;International Immunopharmacology;2024-03

3. Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis;Leukemia;2023-10-17

4. Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia;Frontiers in Oncology;2023-07-05

5. Dysregulated YAP1/Hippo Pathway Contributes to Doxorubicin (ADM) Resistance in Acute Myeloid Leukemia (AML);Current Pharmaceutical Biotechnology;2023-04